Singapore markets open in 5 hours 18 minutes

LLY Jul 2024 520.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
389.770.00 (0.00%)
As of 03:47PM EDT. Market open.
Full screen
Previous close389.77
Open389.70
Bid387.10
Ask392.55
Strike520.00
Expiry date2024-07-19
Day's range389.70 - 389.77
Contract rangeN/A
Volume10
Open interest13
  • Zacks

    FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

    The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.

  • Benzinga

    Pfizer And Roche Advance On Their Weight Loss Drug Journeys

    After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE: LLY) and Novo Nordisk (NYSE: NVO) who are currently dominating the we

  • Benzinga

    Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

    Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday. What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinic